Overcoming the CRS Barrier: Dual-Masked T-Cell Engager VAR5500 Shows Deep PSA Responses in mCRPC

Overcoming the CRS Barrier: Dual-Masked T-Cell Engager VAR5500 Shows Deep PSA Responses in mCRPC

At a recent major oncology conference, Professor Johann de Bono from the Royal Marsden Hospital presented Abstract 17, detailing the preliminary results of a first-in-human Phase 1 dose-escalation trial. The study evaluated VAR5500, a dual-masked pro-X10 T-cell engager targeting PSMA and CD3, in patients with metastatic castration-resistant prostate cancer (mCRPC). This study provides critical proof-of-concept data for the next generation of precision immunotherapy in solid tumors.
Precision Over Prolongation: IPD Meta-Analysis Challenges Routine Hormone Therapy in Recurrent Prostate Cancer

Precision Over Prolongation: IPD Meta-Analysis Challenges Routine Hormone Therapy in Recurrent Prostate Cancer

At the recent oncology conference, Dr. Amar Kishan, Radiation Oncologist at the University of California, Los Angeles (UCLA), presented Abstract 305, a highly anticipated individual patient data (IPD) meta-analysis addressing the optimal patient selection and duration for hormone therapy (HT) combined with post-operative radiotherapy (RT) in recurrent prostate cancer.